Description

CJC-1295 No DAC 5mg + Ipamorelin 5mg (10mg Blend)

This formulation combines two well-characterized growth hormone–axis peptides into a single 10mg blended vial: CJC-1295 No DAC (5mg) and Ipamorelin (5mg). Both compounds are commonly studied for their interaction with endogenous growth hormone (GH) signaling pathways through distinct but complementary receptor mechanisms.

This blend is intended strictly for laboratory and scientific research use.

Mechanism of Action (Research Overview)

CJC-1295 No DAC — GHRH Receptor Pathway

CJC-1295 No DAC is a synthetic analog of growth hormone–releasing hormone (GHRH). It binds to GHRH receptors in the anterior pituitary, stimulating the release of endogenous growth hormone.

The “No DAC” (Drug Affinity Complex) version is short-acting and does not bind to serum albumin, allowing researchers to evaluate more controlled and time-sensitive GH secretion patterns within experimental models.

Ipamorelin — Ghrelin (GHS-R1a) Receptor Pathway

Ipamorelin is a selective growth hormone secretagogue (GHS) that binds to the ghrelin receptor (GHS-R1a). Activation of this receptor stimulates endogenous GH release through a pathway distinct from GHRH receptor activation.

Ipamorelin is frequently studied for its receptor selectivity and minimal activity at unrelated endocrine receptors in controlled laboratory settings.

Dual-Receptor Activation Model

When studied together, CJC-1295 No DAC and Ipamorelin allow researchers to examine:

• Simultaneous activation of GHRH and GHS receptor pathways

• Endogenous GH pulsatility patterns

• Downstream biomarker responses such as IGF-1 and IGFBP-3

• Endocrine feedback loop dynamics

This dual-pathway interaction is a primary reason the blend is frequently evaluated in GH-axis research models.

Research Focus Areas

This peptide blend has been explored in controlled research environments involving:

• Growth hormone secretion modeling

• IGF-1 and IGFBP-3 biomarker tracking

• Pulsatile hormone release analysis

• Metabolic signaling pathway investigation

• Endocrine receptor selectivity studies

• Combined GHRH + GHS activation protocols

These focus areas reflect endpoints measured in published scientific literature and are provided for informational context only.

Key Research Characteristics

• Dual-peptide blend targeting distinct GH-axis receptors

• GHRH analog + selective GHS receptor agonist

• Designed for endogenous GH secretion modeling

• Lyophilized (freeze-dried) for stability and long-term storage

Product Specifications

• Compounds:

  • CJC-1295 No DAC (5mg)

  • Ipamorelin (5mg)

• Total Content: 10mg blended vial

• Form: Lyophilized powder

• Purity: High-purity, lab-tested

• Storage: Store refrigerated after reconstitution

Why Fit Aminos

Fit Aminos provides research-grade peptides manufactured under strict quality control standards to ensure purity, consistency, and reliability. Each batch is tested to support accurate and repeatable laboratory research outcomes.

Important Notice

This product is for research use only. Not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease.